PHILOGEN
Updates & Highlights
Medical Dialogues · about 1 month ago
Sun Pharma Partner Philogen Resubmits EMA Application for Melanoma Therapy Nidlegy
TradingView · about 1 month ago
Philogen SpA Revenue Breakdown – MIL:PHIL
The Globe and Mail · about 1 month ago
Philogen Updates Share Buyback as Treasury Stake Nears 0.9% of Capital
Recent Openings
View all 1 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Competitive Salary
Market-rate compensation
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Equity/Stock Options
Ownership in the company
Remote Work
Work from anywhere flexibility
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at PHILOGEN?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentSun Pharma Partner Philogen Resubmits EMA Application for Melanoma Therapy Nidlegy
Sun Pharma Partner Philogen Resubmits EMA Application for Melanoma Therapy Nidlegy
Medical Dialogues · about 1 month ago
Philogen SpA Revenue Breakdown – MIL:PHIL
Philogen SpA Revenue Breakdown – MIL:PHIL
TradingView · about 1 month ago
Philogen Updates Share Buyback as Treasury Stake Nears 0.9% of Capital
Philogen Updates Share Buyback as Treasury Stake Nears 0.9% of Capital
The Globe and Mail · about 1 month ago
Sun Pharma partner Philogen resubmits Nidlegy application in Europe
Sun Pharma partner Philogen resubmits Nidlegy application in Europe
pharma.economictimes.indiatimes.com · about 1 month ago
Philogen Resubmits Nidlegy EMA Application with 33-Month Follow-Up Data
Philogen Resubmits Nidlegy EMA Application with 33-Month Follow-Up Data
scanx.trade · about 2 months ago
Enterprise value to revenue forward of Philogen SpA – MIL:PHIL
Enterprise value to revenue forward of Philogen SpA – MIL:PHIL
TradingView · 3 months ago
Number of shareholders of Philogen SpA – LSX:A2QQB6
Number of shareholders of Philogen SpA – LSX:A2QQB6
TradingView · 3 months ago
Dividend history of Philogen, Dividend date of Philogen, Dividend data of Philogen, Dividend Calendar of Philogen
Dividend history of Philogen, Dividend date of Philogen, Dividend data of Philogen, Dividend Calendar of Philogen
RTTNews · 4 months ago
Philogen ends Q1 with declining NFP; share buyback launched
Philogen ends Q1 with declining NFP; share buyback launched
marketscreener.com · 4 months ago
Philogen Details Voting Rights Structure Ahead of April 29 Shareholders’ Meeting
Philogen Details Voting Rights Structure Ahead of April 29 Shareholders’ Meeting
TipRanks · 5 months ago
Sun Pharma Partner Philogen Reports Mixed Phase II Results, Plans Registrational Studies
Sun Pharma Partner Philogen Reports Mixed Phase II Results, Plans Registrational Studies
scanx.trade · 6 months ago
PHILOGEN S.p.A. - 2025 10 06 - CS settimanale acquisto azioni proprie
PHILOGEN S.p.A. - 2025 10 06 - CS settimanale acquisto azioni proprie
TradingView · 11 months ago
Philogen S.p.A. (IT0005373789.SG) H1 FY2025 earnings call transcript
Philogen S.p.A. (IT0005373789.SG) H1 FY2025 earnings call transcript
Yahoo Finance · 12 months ago
Philogen withdraws MAA for Nidlegy in EU
Philogen withdraws MAA for Nidlegy in EU
The Pharma Letter · about 1 year ago
Sun Pharma partner Philogen withdraws EU application for skin cancer drug
Sun Pharma partner Philogen withdraws EU application for skin cancer drug
Business Standard · about 1 year ago
Sun Pharma European partner Philogen pulls EMA application for skin cancer drug Nidlegy
Sun Pharma European partner Philogen pulls EMA application for skin cancer drug Nidlegy
Medical Dialogues · about 1 year ago
Sun Pharma, Philogen complete patient enrollment for Cancer Drug Phase-3 Trials, results expected by Q1 FY26
Sun Pharma, Philogen complete patient enrollment for Cancer Drug Phase-3 Trials, results expected by Q1 FY26
ETPharma.com · over 1 year ago
Sun Pharma, Philogen Ink Global Commercialization Deal for Fibromun, an Anti-Cancer Immunotherapy
Sun Pharma, Philogen Ink Global Commercialization Deal for Fibromun, an Anti-Cancer Immunotherapy
Pharmaceutical Executive · almost 2 years ago
EMA validates Philogen-Sun Pharma's MAA for melanoma therapy
EMA validates Philogen-Sun Pharma's MAA for melanoma therapy
Pharmaceutical Technology · about 2 years ago
Philogen
Philogen
The Pharma Letter · about 2 years ago